Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

By afschroeder • August 22, 2026

Oliai CH, Gandhi A, Hoeg RT, Muffly L, Srour SA, Mehta RS, Waller EK, Lowsky R, Patel SS, Dholaria B, Pantin J, Salhotra A, McGuirk JP, Gomez-Arteaga A, Faramand R, Tamari R, Holter-Chakrabarty J, Hamilton BK, Jimenez AMJ, Murray J, Killian MS, Pavlova A, Fernhoff NB, McClellan JS, Abedi M, Negrin RS, Meyer EH. Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. Transplant Cell Ther. 2026 Aug 21:S2666-6367(26)00678-0. doi: 10.1016/j.jtct.2026.08.037. Epub ahead of print. PMID: 42628650.

Tags: allogeneic hematopoietic stem cell transplantation, graft engineered, Hematologic malignancies, Hematology/Oncology, Myeloablative Conditioning, Orca-T, Publications

Related Posts

p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in[...]

Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization

Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong[...]

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC,[...]